Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Depreciation and Depletion (2018 - 2025)

Autolus Therapeutics (AUTL) has disclosed Depreciation and Depletion for 5 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation and Depletion rose 10.53% year-over-year to $2.1 million, compared with a TTM value of $8.2 million through Sep 2025, up 10.81%, and an annual FY2024 reading of $7.6 million, up 15.15% over the prior year.
  • Depreciation and Depletion was $2.1 million for Q3 2025 at Autolus Therapeutics, roughly flat from $2.1 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $2.1 million in Q3 2025 and bottomed at $1.4 million in Q3 2023.
  • Average Depreciation and Depletion over 4 years is $1.8 million, with a median of $1.9 million recorded in 2023.
  • The sharpest move saw Depreciation and Depletion fell 22.22% in 2023, then soared 35.71% in 2024.
  • Year by year, Depreciation and Depletion stood at $1.8 million in 2022, then changed by 0.0% to $1.8 million in 2023, then increased by 11.11% to $2.0 million in 2024, then rose by 5.0% to $2.1 million in 2025.
  • Business Quant data shows Depreciation and Depletion for AUTL at $2.1 million in Q3 2025, $2.1 million in Q2 2025, and $2.0 million in Q1 2025.